Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
US overdose deaths dropped in 2023, the first time since 2018
NEW YORK (AP) — The number of U.S. fatal overdoses fell last year, according to Centers for Disease2024-05-22One in five migratory species at risk of extinction
Thousands of bramblings fly to a German forest for winter. Photo: AFP/DPA2024-05-22'Tenants who have pets often stay'
Greyhound return rates are up and adoption numbers are down, but one potential ACT policy could see2024-05-22KiwiRail in talks to cancel contracts for new Interislander ferries
Photo: RNZ/ Rachel Thomas2024-05-22Who is Abi Carter? Inside the American Idol winner's unconventional family life
California-native Abi Carter was crowned the American Idol winner for season 22 on Sunday. The 21-ye2024-05-22Rātana celebrations begin, discussions from Hui aa Motu expected to continue
Kīngi Tūheitia on the first day of Rātana 2024. Photo: RNZ / Angus Dreaver2024-05-22
atest comment